-
Key Brands
-
Revenue
-
Performance
| Emla | Maltofer | Magnesia Bisurada | Mybulen | Ovestin | Solpadeine | Xylocaine Topicals |
|---|---|---|---|---|---|---|
|
Topical |
Iron |
Antacid |
Analgesic antiinflammatory |
Hormone |
Opioid |
Topical |
Revenue by segment (%)
22%
of Group revenue
29%
of Group gross profit
- Africa Middle East 37
- Australasia 25
- Europe CIS20
- Americas15
- Asia3
Revenue
| Revenue |
2024 R’million |
2023 R’million |
%Change Reported |
CER |
|---|---|---|---|---|
|
Africa Middle East |
3 561 |
3 501 |
2 |
2 |
|
Australasia |
2 430 |
2 278 |
7 |
4 |
|
Europe CIS |
1 974 |
1 742 |
13 |
7 |
|
Americas |
1 450 |
1 323 |
10 |
1 |
|
Asia |
291 |
262 |
11 |
7 |
|
Total |
9 706 |
9 106 |
7 |
3 |
|
Gross profit (%) |
58,7 |
58,6 |
|
|
Source: IQVIA June 2024
Source: IQVIA June 2024
The OTC segment has become the second largest within Commercial Pharmaceuticals and has enjoyed
strong performance across all regions. For FY2024, revenue increased by 7% to R9 706 million, driven
by notable growth in Europe CIS, which saw a 13% rise bolstered by the women’s health portfolio.
Australasia, the second largest OTC region, grew by 7%, benefiting from increased promotional efforts.
The Americas were up 10%, while Africa and the Middle East grew by 2%, with a particularly strong
performance in South Africa during the second half of the year.
The gross profit margin increased slightly to 58,7% (FY2023: 58,6%) due to the favourable impact of the portfolio mix.
The gross profit margin increased slightly to 58,7% (FY2023: 58,6%) due to the favourable impact of the portfolio mix.
